MYCN and neuroblastoma: A structurally similar inhibitor, MLN8054, was shown to inhibit proliferation in neuroblastoma cells and both MLN8054 and alisertib/MLN8237 led to complete response rates of about 50% in a transgenic TH-MYCN mouse model of neuroblastoma [123].